REG - Physiomics PLC - New Head of Biometrics and Two Contracts Awarded

PhysiomicsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250616:nRSP9178Ma&default-theme=true

RNS Number : 9178M  Physiomics PLC  16 June 2025

16 June 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

New Head of Biometrics and Two Contracts Awarded with New Biometrics Client

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce the recruitment of Mr
Jesse Thissen as Head of Biometrics, as well as the signing of the Company's
first ever two Biometrics contracts.

 

Contract Award

The two new contracts are with a UK headquartered clinical-stage
biopharmaceutical company developing immunotherapies that target a range of
diseases. In support of two of the client's active clinical programmes (one
contract per programme), Physiomics' will provide Biostatistical Consulting
and Statistical Programming services starting in July 2025 and continuing over
an initial period of one year. The combined estimated value of both contracts
is £111,000.

 

Head of Biometrics

In addition to these two new contracts, the Company is pleased to announce
that Mr. Jesse Thissen will be joining the team as Head of Biometrics,
effective 1 July 2025. As an experienced biostatistician with a background of
working across Large Pharma (AstraZeneca), Biotech, Consumer Health and
Contract Research Organisations, Jesse will lead the Company's new Biometrics
service-line. Bringing in these initial two new contracts, the Head of
Biometrics will be responsible for delivering them and will be instrumental in
supporting the Company further expand its Biometrics offering and driving
revenue growth in this new area for Physiomics.

 

Biometrics typically comprises three main service areas; Biostatistics;
Statistical Programming; and Data Management. In the short-term, the Company
will focus on driving growth across Biostatistics and Statistical Programming,
as reflected in the two contract awards announced here. The Company does not
envisage developing Data Management capabilities in the short term but will
keep this under close review.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"This is a very exciting time for us here at Physiomics. The recruitment of
Jesse as our Head of Biometrics and these two contract awards mark a
significant milestone in one of the Company's key growth initiatives. In
parallel to remaining committed to growing our modelling and simulation
service-line, the Board and I believe Biometrics will be a key factor in
transforming the business, enabling us to scale more rapidly and meet our
growth aspirations. Due to the complementarity of biometrics with modelling
and simulation, this new service-line will not only enable us to offer a
broader integrated solution to our clients, but allow us to service a much
larger market"

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

About Biometrics

In the context of drug development, Biometrics is an essential component of
clinical research, playing a pivotal role in the setup, conduct and reporting
of clinical trials. It ensures studies are well-designed, data is accurately
collected and analysed, and results are interpreted correctly. Regulatory
authorities across the globe require robust biometrics practices in order to
approve new drugs.

Biometrics typically incorporates three main service areas:

i.          Biostatistics: Supporting the design of clinical studies
and analysis of resulting data.

ii.         Statistical Programming: Use of programming language to
process, analyse and visualise clinical data.

iii.         Data Management: Setup and oversight of the collection,
entry and validation of clinical trial data.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTPKPBPOBKDPAD